MedTrace Logo

Biomarkers Predicting Infectivity in an Experimental Human Influenza Model

NCT03207152 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-07-06

No results posted yet for this study

Summary

This study aims to test the hypothesis that gene transcriptional changes occur within 24 hours of virus exposure in the blood and nasal mucosa, and to identify early biomarker signatures that are predictive of higher viral shedding at the peak of disease

Conditions

Interventions

BIOLOGICAL

Influenza A/California/04/09

Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Imperial College of London

    collaborator UNKNOWN

  • Duke University

    lead OTHER

Principal Investigators

  • Christopher Chiu, BMBCh PhD · Imperial College London

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-11
Primary Completion
2018-05-08
Completion
2019-02-28
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03207152 on ClinicalTrials.gov